There is no single “best” cord blood bank for every family. The right choice depends on whether you want to store your baby’s cord blood privately for your family’s exclusive use or donate it to a public bank where it becomes available to anyone who needs a transplant. Within private banking, the major players differ in pricing, processing technology, storage track record, and accreditation. Here’s what actually matters when comparing them.
Public vs. Private: The First Decision
Before comparing specific companies, you need to decide between public donation and private storage. Public cord blood banks collect, test, and list donated units in a national registry. More than 600,000 units are stored in public banks worldwide, and they’re available to any patient who is a match. Donating is free.
Private banks store your baby’s cord blood exclusively for your family. This costs roughly $1,000 to $2,000 upfront, plus about $100 per year in ongoing storage fees. The appeal is having a guaranteed match available if your child or a sibling ever needs a stem cell transplant. The tradeoff: the odds of actually using it are low. In most countries, only 3 to 4 percent of publicly banked units have been used for transplants, and private bank usage rates are even lower.
There’s an important medical nuance here. Doctors are often reluctant to use a child’s own stored cord blood to treat leukemia, because the sample may already contain pre-leukemic cells, and using your own cells eliminates the beneficial immune response where donor cells attack residual cancer. Cord blood from your own bank also can’t treat genetic diseases, since the stem cells carry the same genetic profile. Where private banking shines is for siblings: a brother or sister’s cord blood can be a lifesaving match for a family member with cancer or an immune disorder.
The Major Private Banks
Three companies have dominated private cord blood banking in the United States for decades. Cryo-Cell, founded in 1989, is the oldest family cord blood bank in the world and serves clients in 87 countries. Viacord launched in 1993 as a subsidiary of ViaCell and was later acquired by PerkinElmer, a large health sciences corporation. Cord Blood Registry (CBR) started in 1995 as a small family company and was purchased by AMAG Pharmaceuticals in 2015.
All three are well-established, but their corporate histories matter. A bank that has changed ownership multiple times may have shifted its policies, pricing, or customer service along the way. When evaluating any bank, check whether the company that enrolled you is the same one holding your sample today.
What to Compare Between Banks
Accreditation
Look for accreditation from AABB (formerly the American Association of Blood Banks) and, ideally, FACT (Foundation for the Accreditation of Cellular Therapy). These organizations audit processing methods, storage conditions, and quality controls. An accredited bank has been independently verified to meet standards that directly affect whether your stored sample will be usable years from now. Any bank you’re considering should be able to confirm current accreditation, not just past certification.
Processing Technology
How a bank processes cord blood before freezing it affects how many viable stem cells survive long-term storage. The goal is to separate and concentrate the stem cells while removing red blood cells and plasma, a step called volume reduction. Automated systems tend to recover a higher percentage of the cells that matter most. One study comparing three processing methods found that an automated system recovered 86% of key stem cells, compared to about 81 to 82% with semi-automated and manual methods. That difference may sound small, but in a transplant scenario, every percentage point of viable cells counts.
Ask prospective banks what processing method they use and whether they can share recovery data. Banks that are transparent about their technology and outcomes are generally more trustworthy than those that deflect technical questions.
Viability and Storage Conditions
Cord blood must be stored at extremely low temperatures to remain viable over decades. The cryoprotectant solution used during freezing and the consistency of storage temperature both influence how many cells survive when the sample is eventually thawed. Research shows that with optimized cryoprotectant formulas, stem cell viability can remain above 82% even after a full year of storage at ultra-low temperatures. With less effective preservation methods, viability can drop below 50%.
Some banks store samples in liquid nitrogen vapor (around negative 190°C), while others use mechanical freezers. Liquid nitrogen systems are generally considered more reliable because they maintain consistent temperatures even during power outages. Ask about backup systems, too. A reputable bank will have redundant cooling, 24-hour monitoring, and a disaster recovery plan for its storage facility.
Pricing Structure
Most private banks charge an initial collection and processing fee between $1,000 and $2,000, then an annual storage fee around $100. Some offer discounts for prepaying multiple years of storage upfront, and many have payment plans. Be cautious of introductory pricing that jumps significantly after the first year, and read the contract carefully for cancellation terms and what happens to your sample if you stop paying.
Some families also choose to bank cord tissue (the umbilical cord itself) alongside the blood, which adds to the cost. Cord tissue contains a different type of stem cell that is being studied for potential future therapies, but no FDA-approved treatments currently use cord tissue stem cells.
What Cord Blood Can Actually Treat
Cord blood stem cells are FDA-recognized for use in blood-forming stem cell transplants. This includes certain blood cancers like leukemia and lymphoma, inherited metabolic disorders, and immune system deficiencies. The stem cells in cord blood can rebuild a patient’s blood and immune system after high-dose chemotherapy or radiation.
Private banks sometimes advertise the potential for cord blood to treat a much broader range of conditions in the future, from cerebral palsy to diabetes. Some early-stage clinical trials are exploring these possibilities, but none have resulted in approved therapies yet. If you’re banking primarily as “biological insurance” against future breakthroughs, understand that this is a speculative investment. The current proven use case is narrow: transplants for blood and immune disorders, most commonly for a sibling rather than the child whose cord blood was stored.
Can Insurance or an HSA Cover the Cost?
In most cases, no. Health insurance, HSAs, and FSAs generally only cover cord blood banking when it’s part of a proven treatment for an existing or imminent medical condition. If your older child has leukemia and you’re banking a new baby’s cord blood as a planned treatment source, that is typically eligible for coverage or reimbursement.
If you’re banking as a precaution with no current medical need, you’ll almost certainly pay out of pocket. Experimental treatments and FDA-approved clinical trials are also excluded from coverage, even if the outcomes look promising. Keep receipts regardless, since tax treatment of medical expenses can vary by situation.
How to Make Your Decision
Start by checking accreditation. Any bank without current AABB accreditation should be eliminated immediately. From there, compare processing technology, storage methods, and pricing transparency. Call the banks you’re considering and ask specific questions: What is your stem cell recovery rate? How do you monitor storage temperatures? What happens to my sample if your company is sold or goes bankrupt?
If you have a family history of blood cancers, immune deficiencies, or inherited metabolic disorders, private banking has a stronger case. If your family has no known risk factors and cost is a concern, donating to a public bank gives your baby’s cord blood a chance to help someone who needs it now, at no cost to you. Many hospitals partner with public banks and can walk you through the donation process during a routine delivery.